Significance of erythrocyte sedimentation rate and c-reactive protein as predictive factors for prognosis in non-metastatic renal cell carcinoma

Korean Journal of Urology

Volumn 47, Issue 10, 2006, Pages 1059-1064

  Kim, Young Kyun ^a   Kim, Sun Il ^a   Kim, Se Joong ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

C reactive protein; Erythrocyte sedimentation rate; Prognosis; Renal cell carcinoma

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; NEPHRECTOMY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROGNOSIS; RECURRENCE RISK; TUMOR VOLUME; UNIVARIATE ANALYSIS;

EID: 33751361489     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2006.47.10.1059     Document Type: Article

References (25)

1. Gudbjartsson T, Thoroddsen A, Petursdottir V, Hardarson S, Magnusson J, Einarsson GV. Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. Urology 2005;66:1186-91
2. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663-71
3. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159:1163-7
4. Ljungberg B, Grankvist K, Rasmuson T. Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 1995;76:1435-9
5. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000;34:246-51
6. Masuda H, Kurita Y, Suzuki K, Fujita K, Aso Y. Predictive value of serum immunosuppressive acidic protein for staging renal cell carcinoma: comparison with other tumour markers. Br J Urol 1997;80:25-9
7. Sung KT, Park NC, Yoon JB. Clinicopathological study of renal cell carcinoma: prognostic factors. Korean J Urol 1990; 31:29-36
8. Hwang C, Chang SG. Clinical significance of serum C-reactive protein in patients with renal cell carcinoma. Korean J Urol 1999;40:864-8
9. Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician 1999;60:1443-50
10. Johansson JE, Sigurdsson T, Holmberg L, Bergstrom R. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. An analysis of prognostic factors in 300 population-based consecutive cases. Cancer 1992;70:1556-63
11. Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005;18:146-50
12. Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 1991;114:361-5
13. Dönmez T, Kale M, Özyürek Y, Atalay H. Erythrocyte sedimentation rates in patients with renal cell carcinoma. Eur Urol 1992;21(Suppl 1):51-2
14. Miyata Y, Koga S, Nishikido M, Noguchi M, Kanda S, Hayashi T, et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001; 58:161-4
15. Lehmann J, Retz M, Nürnberg N, Schnöckel U, Raffenberg U, Krams M, et al. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 2004;101:1552-62
16. Inoue T, Hashimura T, Iwamura H, Takahashi T, Segawa T, Kakehi Y, et al. Multivariate analysis of prognostic determinants after surgery for renal cell carcinoma at Himeji National Hospital. Hinyokika Kiyo 2000;46:229-34
17. Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 1998;5:418-22
18. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997;33:1794-8
19. Atzpodien J, Royston P, Wandert T, Reitz M; DGCIN-German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. Metastatic renal cell carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348-53
20. Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 2005;173:52-5
21. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon- α. Eur J Cancer 1994;30A:1310-4
22. Sengupta S, Lohse CM, Cheville JC, Leibovich BC, Thompson RH, Webster WS, et al. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 2006;106:304-12
23. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:992-3
24. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63
25. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med 1999;17:1019-25